GET DAILY SIGNALSREGENXBIO (RGNX) Q3 2026 Results: Narrowed Loss and Solid Cash Runway Support Late-Stage Pipeline
Key Takeaways
- REGENXBIO reported third quarter 2026 revenue of $9.16 million, down from $29.73 million in the same period a year earlier.
- Net loss narrowed to $40.74 million, compared with a net loss of $61.94 million in Q3 2025.
- Loss per share was $0.62, ahead of analyst consensus, while revenue came in below estimates.
- The company ended the quarter with $251 million in cash, cash equivalents, and marketable securities, funding operations into late 2027.
- Topline results from the pivotal ATMOSPHERE and ASCENT studies in wet age-related macular degeneration (AMD) are expected before the end of 2026.
Earnings Context and Pipeline Importance
REGENXBIO operates as a clinical-stage biotechnology company centered on its proprietary adeno-associated virus (AAV) gene therapy delivery platform. For a pre-revenue business like this, quarterly results provide the most value through insights into cash runway and progress on late-stage programs rather than near-term sales. I pay particular attention to the sura-vec program in wet AMD, which is advancing in partnership with AbbVie, along with RGX-202 for Duchenne muscular dystrophy. With pivotal data readouts and a planned regulatory filing on the horizon, this update serves as a useful checkpoint on the company’s ability to reach those milestones without immediate financing pressure.
Reported Financials
For the third quarter ended September 30, 2026, REGENXBIO posted total revenue of $9.16 million, compared with $29.73 million in the prior-year quarter. License and royalty revenue declined to $5.24 million from $23.61 million, and service revenue was $3.92 million versus $6.13 million. The net loss improved to $40.74 million, or $0.62 per share, from a net loss of $61.94 million, or $1.20 per share, in Q3 2025. Loss per share beat consensus estimates, although revenue fell short of expectations.
The company closed the quarter with $251 million in cash, cash equivalents, and marketable securities, an increase from $241 million at the end of 2025. This figure incorporates a $100 million milestone payment from AbbVie received in July 2026 and roughly $108 million in net proceeds from an underwritten public offering. It excludes a $39 million payment received in October 2026 under a settlement agreement with Sarepta Therapeutics.
Market Reaction and Ongoing Sentiment
REGENXBIO shares have remained under pressure throughout 2026 as investors balance pipeline risks against the potential of its gene therapy candidates. The latest results presented a mixed picture, with the narrower loss per share offset by softer revenue. For a clinical-stage company, however, attention stays firmly on upcoming catalysts. Management confirmed that the BLA submission for RGX-202 is still planned for the first quarter of 2027, with potential accelerated approval in the second half of 2027, while pivotal wet AMD data are anticipated before year-end. Those events are likely to influence positioning more than the quarterly numbers themselves.
Forward Catalysts and Cash Management
The next major milestone is the topline readout from the ATMOSPHERE and ASCENT pivotal studies of sura-vec in wet AMD, expected in the fourth quarter of 2026. These results, to be announced with AbbVie, will test whether a one-time gene therapy can ease the need for frequent anti-VEGF injections while preserving vision.
Investors will also follow the RGX-202 program in Duchenne muscular dystrophy. The company intends to submit a full BLA in the first quarter of 2027 under the accelerated approval pathway, targeting potential U.S. approval in the second half of 2027. Outside the U.S., the randomized AFFINITY RISE trial is slated to begin in the first half of 2027.
Cash discipline remains central. The company has guided to a runway extending into the late fourth quarter of 2027, without assuming further non-dilutive funding. Ongoing ZOLGENSMA and ITVISMA royalties, possible future milestones, and controlled spending will matter as REGENXBIO moves toward commercialization.
Using Tickeron’s AI Screener in Biotech Research
When evaluating names in the biotech space, I find Tickeron’s AI Screener helpful for quickly filtering companies by industry, market cap, technical patterns, and performance metrics. It surfaces relevant comparables and trend signals that complement traditional fundamental work, allowing me to place individual reports like this one in broader context without spending excessive time on manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RGNX in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026
RGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 31 cases where RGNX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on RGNX as a result. In 80 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for RGNX just turned positive on October 28, 2026. Looking at past instances where RGNX's MACD turned positive, the stock continued to rise in 45 of 54 cases over the following month. The odds of a continued upward trend are 83%.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNX advanced for three days, in 224 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for RGNX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. RGNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.789) is normal, around the industry mean (2.788). P/E Ratio (-1.952) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (6.110) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (2.386) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of gene therapy treatments
Industry Biotechnology
Advertisement